Activation of PI3Kα by physiological effectors and by oncogenic mutations: Structural and dynamic effects

Biophysical Reviews

Volumn 6, Issue 1, 2014, Pages 89-95

  Gabelli, Sandra B ^a   Echeverria, Ignacia ^a   Alexander, Megan ^a   Duong Ly, Krisna C ^a   Chaves Moreira, Daniele ^a   Brower, Evan T ^b   Vogelstein, B ^b   Amzel, L Mario ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

p85; PI3K; PIK3CA; PIK3R1; PIP2; PIP3; Somatic mutation

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE; PROTEIN P110; PROTEIN TYROSINE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG;

GENE MUTATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; X RAY DIFFRACTION;

EID: 84897820841     PISSN: 18672450     EISSN: 18672469     Source Type: Journal    
DOI: 10.1007/s12551-013-0131-1     Document Type: Review

References (39)

1. Atilgan A, Durell S et al (2001) Anisotropy of fluctuation dynamics of proteins iwth an elastic network model. Biophys J 80(1): 505-515.
2. Bachman KE, Argani P et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3(8): 772-775.
3. Berndt A, Miller S et al (2010) The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 6(3): 244.
4. Broderick DK, Di C et al (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64(15): 5048-5050.
5. Burke JE, Perisic O et al (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci USA 109(38): 15259-15264In this paper the dynamics of PI3K are analyzed by hydrogen deuterium exchange mass spectrometry. It Identifies regions of enhanced dynamics in the heterodimer.
6. Burke JE, Vadas O et al (2011) Dynamics of the phosphoinositide 3-kinase p110delta interaction with p85alpha and membranes reveals aspects of regulation distinct from p110alpha. Structure 19(8): 1127-1137.
7. Campbell IG, Russell SE et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21): 7678-7681.
8. Carson JD, van Aller G et al (2008) Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 409(2): 519-524.
9. Certal V, Halley F et al (2012) Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kbeta inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. J Med Chem 55(10): 4788-4805.
10. Cgarn CGARN (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216): 1061-1068.
11. Dhand R, Hara K et al (1994) PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J 13(3): 511-521.
12. Engelman JA, Luo J et al (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8): 606-619.
13. Eyal, E., A. Dutta, et al. (2011) Cooperative dynamics of proteins unraveled by network models. WIREs Computational Molecular Science 1 (May-June).
14. Forbes SA, Bindal N et al (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39(Database issue): D945-D950.
15. Gabelli SB, Mandelker D et al (2010) Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design. Biochim Biophys Acta 1804(3): 533-540.
16. Geering B, Cutillas PR et al (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci USA 104(19): 7809-7814.
17. Gur M, Zomot E et al (2013) Global motions exhibited by proteins in micro- to milliseconds simulations concur with anisotropic network model predictions. J Chem Phys 139(121912).
18. Gymnopoulos M, Elsliger MA et al (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104(13): 5569-5574.
19. Holt KH, Olson L et al (1994) Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits. Mol Cell Biol 14(1): 42-49.
20. Hon WC, Berndt A et al (2012) Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene 31(32): 3655-3666.
21. Huang CH, Mandelker D et al (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857): 1744-1748 This paper describes the structure of the p110/nip85 heterodimer and identifies the high mutation regions in the structure.
22. Kang S, Bader AG et al (2004) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102(3): 802-807.
23. Katso R, Okkenhaug K et al (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675.
24. Lee JW, Soung YH et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8): 1477-1480.
25. Levine DA, Bogomolniy F et al (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11(8): 2875-2878.
26. Mandelker D, Gabelli SB et al (2009) A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A 106(40): 16996-17001.
27. Miled N, Yan Y et al (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835): 239-242.
28. Murray JM, Sweeney ZK et al (2012) Potent and highly selective benzimidazole inhibitors of PI3-kinase delta. J Med Chem 55(17): 7686-7695.
29. Nolte RT, Eck MJ et al (1996) "Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes". Nat Struct Biol 3(4): 364-374.
30. Rudd ML, Price JC et al (2011) A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 17(6): 1331-1340.
31. Samuels Y, Wang Z et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670): 554.
32. Shepherd PR, Siddle K et al (1997) Is stimulation of class-1 phosphatidylinositol 3-kinase activity by insulin sufficient to activate pathways involved in glucose metabolism. Biochem Soc Trans 25(3): 978-981.
33. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346(Pt 3): 561-576.
34. Vanhaesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253(1): 239-254.
35. Vogt PK, Kang S et al (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32(7): 342-349.
36. Walker EH, Perisic O et al (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402(6759): 313-320.
37. Wu H, Yan Y et al (2007) Regulation of class IA PI3Ks. Biochem Soc Trans 35(Pt 2): 242-244.
38. Zhao L, Vogt PK (2008a) Class I PI3K in oncogenic cellular transformation. Oncogene 27(41): 5486-5496.
39. Zhao L, Vogt PK (2008b) Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105(7): 2652-2657.